Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4+ T cell activation and HIV-1 latency reversal.

Cao S, Slack SD, Levy CN, Hughes SM, Jiang Y, Yogodzinski C, Roychoudhury P, Jerome KR, Schiffer JT, Hladik F, Woodrow KA.

Sci Adv. 2019 Mar 27;5(3):eaav6322. doi: 10.1126/sciadv.aav6322. eCollection 2019 Mar.

2.

In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia.

McGuffin SA, Bharadwaj R, Gonzalez-Cuyar LF, Schiffer JT, Stacey AW, Walter RB, Duke ER.

Clin Infect Dis. 2019 Jan 18;68(3):525-529. doi: 10.1093/cid/ciy394. No abstract available.

PMID:
30657904
3.

A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.

Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT.

Nat Commun. 2018 Nov 16;9(1):4811. doi: 10.1038/s41467-018-06843-5.

4.
5.

Herpes simplex virus-2 dynamics as a probe to measure the extremely rapid and spatially localized tissue-resident T-cell response.

Schiffer JT, Swan DA, Prlic M, Lund JM.

Immunol Rev. 2018 Sep;285(1):113-133. doi: 10.1111/imr.12672. Review.

6.

A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection.

Schiffer JT, Swan DA, Roychoudhury P, Lund JM, Prlic M, Zhu J, Wald A, Corey L.

J Immunol. 2018 Sep 1;201(5):1522-1535. doi: 10.4049/jimmunol.1800471. Epub 2018 Jul 25.

7.

Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

Roychoudhury P, De Silva Feelixge H, Reeves D, Mayer BT, Stone D, Schiffer JT, Jerome KR.

BMC Biol. 2018 Jul 11;16(1):75. doi: 10.1186/s12915-018-0544-1.

8.

Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants.

Boucoiran I, Mayer BT, Krantz EM, Marchant A, Pati S, Boppana S, Wald A, Corey L, Casper C, Schiffer JT, Gantt S.

Pediatr Infect Dis J. 2018 Jul;37(7):627-631. doi: 10.1097/INF.0000000000001877.

9.

Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.

Spicknall IH, Looker KJ, Gottlieb SL, Chesson HW, Schiffer JT, Elmes J, Boily MC.

Vaccine. 2018 Apr 3. pii: S0264-410X(18)30254-8. doi: 10.1016/j.vaccine.2018.02.067. [Epub ahead of print]

10.

Reply to Giménez et al.

Hill JA, Mayer BT, Xie H, Leisenring WM, Boeckh M, Schiffer JT.

Clin Infect Dis. 2018 Aug 16;67(5):807-808. doi: 10.1093/cid/ciy139. No abstract available.

11.

Model-based estimation of superinfection prevalence from limited datasets.

Reeves DB, Magaret AS, Greninger AL, Johnston C, Schiffer JT.

J R Soc Interface. 2018 Feb;15(139). pii: 20170968. doi: 10.1098/rsif.2017.0968.

12.

Myeloablation-associated deletion of ORF4 in a human coronavirus 229E infection.

Greninger AL, Pepper G, Shean RC, Cent A, Palileo I, Kuypers JM, Schiffer JT, Jerome KR.

NPJ Genom Med. 2017 Oct 9;2:30. doi: 10.1038/s41525-017-0033-4. eCollection 2017.

13.

Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children.

Matrajt L, Gantt S, Mayer BT, Krantz EM, Orem J, Wald A, Corey L, Schiffer JT, Casper C.

Sci Rep. 2017 Oct 12;7(1):13105. doi: 10.1038/s41598-017-12994-0.

14.

Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation.

Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Jerome KR, Zerr DM, Nichols G, Boeckh M, Schiffer JT.

Clin Infect Dis. 2018 Jan 18;66(3):368-375. doi: 10.1093/cid/cix804.

15.

Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Schiffer JT, Gottlieb SL.

Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273-2. doi: 10.1016/j.vaccine.2017.09.044. [Epub ahead of print]

16.

Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.

Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, Boily MC.

Lancet Infect Dis. 2017 Dec;17(12):1303-1316. doi: 10.1016/S1473-3099(17)30405-X. Epub 2017 Aug 23. Review.

17.

Reply to "Early Stochastic Dynamics in Human Cytomegalovirus Infection".

Gantt S, Mayer BT, Schiffer JT.

J Virol. 2017 Aug 24;91(18). pii: e01006-17. doi: 10.1128/JVI.01006-17. Print 2017 Sep 15. No abstract available.

18.

Anti-proliferative therapy for HIV cure: a compound interest approach.

Reeves DB, Duke ER, Hughes SM, Prlic M, Hladik F, Schiffer JT.

Sci Rep. 2017 Jun 21;7(1):4011. doi: 10.1038/s41598-017-04160-3.

19.

Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia.

Reeves DB, Peterson CW, Kiem HP, Schiffer JT.

J Virol. 2017 Jun 9;91(13). pii: e00095-17. doi: 10.1128/JVI.00095-17. Print 2017 Jul 1.

20.

Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells.

Mayer BT, Krantz EM, Swan D, Ferrenberg J, Simmons K, Selke S, Huang ML, Casper C, Corey L, Wald A, Schiffer JT, Gantt S.

J Virol. 2017 May 26;91(12). pii: e00380-17. doi: 10.1128/JVI.00380-17. Print 2017 Jun 15.

21.

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Sorror ML, Sandmaier BM, Nichols G, Zerr DM, Jerome KR, Schiffer JT, Boeckh M.

Blood. 2017 Apr 20;129(16):2316-2325. doi: 10.1182/blood-2016-10-748426. Epub 2017 Feb 16.

22.

Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants.

Mayer BT, Matrajt L, Casper C, Krantz EM, Corey L, Wald A, Gantt S, Schiffer JT.

J Infect Dis. 2016 Dec 1;214(11):1735-1743. Epub 2016 Sep 20.

23.

Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.

Schiffer JT, Swan DA, Magaret A, Schacker TW, Wald A, Corey L.

PLoS One. 2016 Jun 10;11(6):e0155124. doi: 10.1371/journal.pone.0155124. eCollection 2016.

24.

Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases.

Roychoudhury P, De Silva Feelixge HS, Pietz HL, Stone D, Jerome KR, Schiffer JT.

J Antimicrob Chemother. 2016 Aug;71(8):2089-99. doi: 10.1093/jac/dkw104. Epub 2016 Apr 18.

25.

Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants.

Gantt S, Orem J, Krantz EM, Morrow RA, Selke S, Huang ML, Schiffer JT, Jerome KR, Nakaganda A, Wald A, Casper C, Corey L.

J Infect Dis. 2016 Jul 1;214(1):36-44. doi: 10.1093/infdis/jiw076. Epub 2016 Feb 24.

26.

A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population.

Dimitrov DT, Kiem HP, Jerome KR, Johnston C, Schiffer JT.

Sci Rep. 2016 Feb 24;6:22183. doi: 10.1038/srep22183.

27.

Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons.

Bender Ignacio RA, Goldman JD, Magaret AS, Selke S, Huang ML, Gantt S, Johnston C, Phipps WT, Schiffer JT, Zuckerman RA, McClelland RS, Celum C, Corey L, Wald A, Casper C.

Infect Agent Cancer. 2016 Feb 10;11:7. doi: 10.1186/s13027-016-0052-2. eCollection 2016.

28.

Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.

Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.

Sci Transl Med. 2016 Feb 3;8(324):324ra15. doi: 10.1126/scitranslmed.aad6654.

29.

Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.

De Silva Feelixge HS, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, Aubert M, Jerome KR.

Antiviral Res. 2016 Feb;126:90-8. doi: 10.1016/j.antiviral.2015.12.007. Epub 2015 Dec 22.

30.

Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis.

Mayer BT, Srinivasan S, Fiedler TL, Marrazzo JM, Fredricks DN, Schiffer JT.

J Infect Dis. 2015 Sep 1;212(5):793-802. doi: 10.1093/infdis/jiv079. Epub 2015 Feb 12.

31.

Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection.

Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, Magaret A, Corey L, Wald A.

J Pediatr. 2015 Apr;166(4):827-33. doi: 10.1016/j.jpeds.2014.11.011. Epub 2014 Dec 6.

32.

Herpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.

Dhankani V, Kutz JN, Schiffer JT.

PLoS Comput Biol. 2014 Nov 6;10(11):e1003922. doi: 10.1371/journal.pcbi.1003922. eCollection 2014 Nov.

33.

AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication.

Weber ND, Stone D, Sedlak RH, De Silva Feelixge HS, Roychoudhury P, Schiffer JT, Aubert M, Jerome KR.

PLoS One. 2014 May 14;9(5):e97579. doi: 10.1371/journal.pone.0097579. eCollection 2014.

34.

Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding.

Schiffer JT, Mayer BT, Fong Y, Swan DA, Wald A.

J R Soc Interface. 2014 Mar 26;11(95):20140160. doi: 10.1098/rsif.2014.0160. Print 2014 Jun 6.

35.

The majority of CD4+ T-cell depletion during acute simian-human immunodeficiency virus SHIV89.6P infection occurs in uninfected cells.

Matrajt L, Younan PM, Kiem HP, Schiffer JT.

J Virol. 2014 Mar;88(6):3202-12. doi: 10.1128/JVI.03428-13. Epub 2014 Jan 3.

36.

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.

Schiffer JT, Swan DA, Corey L, Wald A.

Antimicrob Agents Chemother. 2013 Dec;57(12):5820-9. doi: 10.1128/AAC.01114-13. Epub 2013 Sep 9.

37.

Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection.

Schiffer JT.

Front Immunol. 2013 Jul 29;4:209. doi: 10.3389/fimmu.2013.00209. eCollection 2013.

38.

Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach.

Schiffer JT, Swan DA, Stone D, Jerome KR.

PLoS Comput Biol. 2013;9(7):e1003131. doi: 10.1371/journal.pcbi.1003131. Epub 2013 Jul 4.

39.

Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.

Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L.

Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.

40.

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Schiffer JT, Corey L.

Nat Med. 2013 Mar;19(3):280-90. doi: 10.1038/nm.3103.

41.

CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence.

Jing L, Schiffer JT, Chong TM, Bruckner JJ, Davies DH, Felgner PL, Haas J, Wald A, Verjans GM, Koelle DM.

J Virol. 2013 Mar;87(5):2617-27. doi: 10.1128/JVI.03047-12. Epub 2012 Dec 19.

42.

Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes.

Moss NJ, Magaret A, Laing KJ, Kask AS, Wang M, Mark KE, Schiffer JT, Wald A, Koelle DM.

J Virol. 2012 Sep;86(18):9952-63. doi: 10.1128/JVI.00829-12. Epub 2012 Jul 3.

43.

Targeted DNA mutagenesis for the cure of chronic viral infections.

Schiffer JT, Aubert M, Weber ND, Mintzer E, Stone D, Jerome KR.

J Virol. 2012 Sep;86(17):8920-36. doi: 10.1128/JVI.00052-12. Epub 2012 Jun 20. Review.

44.

Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy.

Schouten JT, Schiffer JT.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):68-71. doi: 10.1097/QAI.0b013e31824bed3f.

45.

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A.

Lancet. 2012 Feb 18;379(9816):641-7. doi: 10.1016/S0140-6736(11)61750-9. Epub 2012 Jan 4. Erratum in: Lancet. 2012 Feb 18;379(9816):616.

46.

Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy.

Schiffer JT, Magaret A, Selke S, Corey L, Wald A.

J Antimicrob Chemother. 2011 Nov;66(11):2593-600. doi: 10.1093/jac/dkr346. Epub 2011 Aug 24.

47.

The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Schiffer JT, Wald A, Selke S, Corey L, Magaret A.

J Infect Dis. 2011 Aug 15;204(4):554-61. doi: 10.1093/infdis/jir314.

48.

A siege of hepatitis: fighting a defiant virus.

Schiffer JT, Scott J, Corey L.

Nat Med. 2011 Mar;17(3):253-4. doi: 10.1038/nm0311-253. No abstract available.

PMID:
21383719
49.

HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Abu-Raddad LJ, Schiffer JT, Ashley R, Mumtaz G, Alsallaq RA, Akala FA, Semini I, Riedner G, Wilson D.

Epidemics. 2010 Dec;2(4):173-82. doi: 10.1016/j.epidem.2010.08.003. Epub 2010 Sep 15. Review.

50.

Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes.

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18973-8. doi: 10.1073/pnas.1006614107. Epub 2010 Oct 18.

Supplemental Content

Loading ...
Support Center